PX1 Research has launched a line of US-manufactured sublingual peptide strips designed for needle-free research applications, with formulations covering Retatrutide, Tirzepatide, and BPC-157. The introduction marks a shift in how academic and institutional researchers can access peptide compounds, moving away from injectable formats toward a non-invasive oral delivery method produced under domestic quality control standards.
Each strip in the new line is manufactured within the United States under current Good Manufacturing Practice (cGMP) protocols, a set of quality control standards enforced throughout the production process. Every batch undergoes High-Performance Liquid Chromatography (HPLC) purity verification, with results confirming 99% or greater purity across formulations. Accompanying each product is a Certificate of Analysis, providing researchers with documented evidence of the batch composition before use. The decision to manufacture domestically reflects a broader emphasis on supply chain transparency. Researchers sourcing compounds for institutional projects often require documentation trails that trace production conditions, and domestic cGMP-compliant manufacturing supports that requirement directly.
Among the available formulations, dissolving Retatrutide strips have drawn particular attention given the compound's presence in ongoing metabolic and weight regulation research. Tirzepatide and BPC-157 are also included in the lineup, extending coverage to compounds associated with glucose regulation and tissue repair research respectively. The sublingual delivery format allows the strip to dissolve under the tongue, enabling absorption without the use of needles or syringes. For research environments where non-invasive administration methods are a design requirement - whether due to protocol specifications, institutional review considerations, or participant-facing study designs - this format addresses a logistical gap that injectable peptide formats cannot.
The full product line is accessible through PX1 Research, with specific information on dissolving Retatrutide strips available directly on the product page.
PX1 Research has positioned these sublingual peptide strips specifically for academic and institutional research contexts. The strips are not intended for clinical, therapeutic, or human consumption use. Rather, the product addresses demand from researchers who require compounds delivered in a format compatible with non-invasive study designs, where traditional needle-based administration would introduce procedural variables or ethical complications. The inclusion of BPC-157 alongside GLP-1 receptor agonist-class compounds such as Retatrutide and Tirzepatide signals that the line is intended to serve a range of research disciplines. Each compound presents distinct molecular properties, and the sublingual strip format has been adapted to accommodate the specific stability and absorption characteristics relevant to each formulation.
